Medicsight Share Discussion Threads

[moverman] 21/6/2007 11:16

not showing here for some reason but take a look at yahoo

[trasenster] 21/6/2007 10:10

How do you see the trades?

[moverman] 21/6/2007 08:56

looks well supported nice uplift from 110p placing rock and roll moverman

[damanko] 21/6/2007 08:04

From the same "stable" as Accsys Technologies, which floated on AIM at One Euro per share October 2005. Accsys now trading at an awful lot less than it did....

CHARTS

Website, history etc:

Also:

Also:

21 June 2007

The London Stock Exchange is pleased to welcome Medicsight plc to AIM.

Medicsight is the industry leader in the development of Computer-Aided Detection (CAD) and image analysis software to assist in the early detection and diagnosis of disease.

Medicsight helps radiologists analyse Computed Tomography ("CT") scans to detect and diagnose abnormalities and to monitor them accurately over time. Medicsight's CAD software has been validated using one of the world's most comprehensive databases of verified CT scan data.

Medicsight's currently marketed products include ColonCAD™ and COLON CAR™, and LungCAD™ and LUNG CAR™ which aid the early detection of cancers, with significant global mortality and morbidity.

Admission to trading follows a Placing of the Company's Ordinary Shares, which raised £32 million before expenses at the Placing Price of £1.10 pence per share. The company will have a market capitalisation of £171 million based on the Placing price.

Commenting today, David Sumner, Chief Executive Officer of Medicsight, said: "We would like to thank our existing and new shareholders for their support. They have recognised the benefits of CAD technology and the substantial opportunities for Medicsight in the medical imaging market. Joining AIM will allow us to aggressively drive the sales of Medicsight's CAD products as well as enabling us to introduce new products to the company's portfolio through a combination of internal R&D and acquisitions."

Collins Stewart Europe Limited is acting as Nominated Adviser and Broker.


Medicsight plc is a UK-headquartered, research driven developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD(TM)and LungCAD(TM)software products are integrated with the advanced 3D visualisation workstations of several industry-leading imaging visualisation application software and equipment partners. The core focus of the Company's product development has been on developing technology that is used alongside Multi Detector Computer Tomography (MDCT) scanners. MDCT scanning is clinically recognised as a reliable, quick, safe and non-invasive examination for the detection of colon and lung cancer. However, interpretation and analysis of CT scan data is labour intensive and can be subject to human error. The application of Medicsight's CAD products is to aid detection and diagnosis in asymptomatic and symptomatic patients and to support diagnostic decision-making and treatment planning through the identification and measurement tracking of lesions. The Directors expect the proceeds of the placing to drive the uptake and distribution of the existing ColonCAD and LungCAD products (offices have been established in the USA, Japan and China specifically for this purpose); continued investment to improve clinical awareness and validation; actively promote CAD through the support of accredited training programs; and introduce additional products into the Company's portfolio by a combination of internal research and development and acquisitions.